Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Oktober 2023 09:00 ET | Quelle: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer

More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapyAbout half never or almost never felt sexual desire or...
02. Oktober 2023 09:00 ET | Quelle: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms

Results showed that younger age, non-visceral disease, prior tamoxifen and a longer total duration of AI use may be associated with higher baseline vaginal and/or vulvar symptomatologyFindings were...
29. Juni 2023 09:00 ET | Quelle: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting

One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancerSecond poster shares survey results examining vaginal and sexual health in ER+/HER2-...